Company summary
Dr. Martens is a global footwear brand best known for its distinctive boots and shoes with air-cushioned soles. Products are sold through its own stores and websites as well as wholesale partners.
← Back to the 350
DOCS
Dr. Martens
Retailers
- Index
- FTSE 250
- ISIN
- Not specified
- Book status
- 2026 edition — current
Key activities
Design, sourcing, marketing and sale of boots, shoes, sandals and accessories through direct-to-consumer stores, e-commerce and wholesale distribution.
Key markets
The Americas, EMEA and Asia-Pacific, with the United States a particularly important market for brand growth and profitability.
Key drivers
Brand demand, US recovery, full-price sales, direct-to-consumer growth, wholesale orders, new product launches, inventory discipline and successful execution of the turnaround strategy.
Key risks
Fashion and brand risk, weak discretionary spending, wholesale volatility, excess inventory, discounting, currency movements, sourcing disruption and failure to rebuild US demand.
Recent Developments
19 May 2026: FY2026 adjusted pre-tax profit rose 61% to £55m despite revenue falling 2.9% to £764.9m. Full-price US retail sales rose strongly, supporting management's view that its consumer-first turnaround is gaining traction.
Dividend notes
Pays interim and final dividends. The 0.85p interim dividend went ex-dividend on 5 March 2026 and was paid on 9 April. The 1.70p final dividend goes ex-dividend on 27 August and is payable on 7 October, taking FY2026 total dividends to 2.55p.
The complete 350 Trade Book — 350 leading UK-listed companies, presented in one consistent working reference.